Resolution of recalcitrant human papillomavirus gingival infection with topical cidofovir.

Abstract

Cidofovir, a purine nucleotide analogue of cytosine, is a promising new drug that acts against a wide number of DNA viruses. In 1997, the Food and Drug Administration approved intravenous cidofovir for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Recent studies have shown cidofovir (1% gel or cream) to be effective for the treatment of recalcitrant and unmanageable viral cutaneous lesions induced by herpes, pox, and papillomavirus families. We report the case of a 45-year-old man who had been diagnosed as having acquired immunodeficiency syndrome in 1995. Recalcitrant to conventional therapies, the human papillomavirus lesions on his gingival mucosa were successfully treated with cidofovir 1% cream. To the best of our knowledge, this is the first case in which topical cidofovir has been used for the treatment of a human papillomavirus infection of the oral mucosa.

• Authors: D Calista
• Journal: Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics (Oral Surg Oral Med Oral Pathol Oral Radiol Endod) Vol. 90 Issue 6 Pg. 713-5 (Dec 2000) ISSN: 1079-2104 [Print] United States
• PMID: 11113816 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Infective Agents, Local
• Antiviral Agents
• Organophosphonates
• Organophosphorus Compounds
• Cytosine
• Cidofovir

Topics

• Anti-Infective Agents, Local (therapeutic use)
• Antiviral Agents (administration & dosage, therapeutic use)
• Cidofovir
• Cytosine (administration & dosage, analogs & derivatives, therapeutic use)
• Gingival Diseases (complications, drug therapy, virology)
• HIV Infections (complications)
• Humans
• Inclusion Bodies, Viral
• Male
• Middle Aged
• Organophosphonates
• Organophosphorus Compounds (administration & dosage, therapeutic use)
• Papillomaviridae (isolation & purification)
• Papillomavirus Infections (drug therapy)